[go: up one dir, main page]

BR0115989A - Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido - Google Patents

Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido

Info

Publication number
BR0115989A
BR0115989A BR0115989-5A BR0115989A BR0115989A BR 0115989 A BR0115989 A BR 0115989A BR 0115989 A BR0115989 A BR 0115989A BR 0115989 A BR0115989 A BR 0115989A
Authority
BR
Brazil
Prior art keywords
suspension
acid
active ingredient
pharmaceutical preparation
labile active
Prior art date
Application number
BR0115989-5A
Other languages
English (en)
Inventor
Rango Dietrich
Rudolf Linder
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of BR0115989A publication Critical patent/BR0115989A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PREPARAçãO FARMACêUTICA NA FORMA DE UMA SUSPENSãO COMPREENDENDO UM INGREDIENTE ATIVO INSTáVEL A áCIDO". A presente invenção refere-se ao campo da tecnologia farmacêutica e descreve uma nova preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido, em particular um inibidor de bomba de próton instável a ácido. A invenção também refere-se a processos para produzir a suspensão. A suspensão é particularmente adequada para administração de ingredientes ativos instáveis a ácido a pessoas que têm dificuldade de deglutir formas de dosagem sólidas como comprimidos ou cápsulas.
BR0115989-5A 2000-12-07 2001-12-05 Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido BR0115989A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126829 2000-12-07
PCT/EP2001/014254 WO2002045692A1 (en) 2000-12-07 2001-12-05 Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
BR0115989A true BR0115989A (pt) 2004-01-13

Family

ID=8170596

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115989-5A BR0115989A (pt) 2000-12-07 2001-12-05 Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido

Country Status (10)

Country Link
US (1) US7357943B2 (pt)
EP (1) EP1341523B1 (pt)
JP (1) JP5009482B2 (pt)
KR (1) KR20030059318A (pt)
CN (1) CN100528232C (pt)
AU (1) AU2002234545A1 (pt)
BR (1) BR0115989A (pt)
CA (1) CA2430824C (pt)
ES (1) ES2403238T3 (pt)
WO (1) WO2002045692A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2004004690A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
WO2004063152A2 (en) * 2003-01-10 2004-07-29 Transform Pharmaceuticals, Inc. Lansoprazole formulations and related processes and methods
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
CA2601250C (en) * 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
CA2606861C (en) * 2005-05-05 2012-08-07 Sanofi-Aventis U.S. Llc Stable nanoparticle formulations
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
US20100029241A1 (en) * 2008-08-01 2010-02-04 Justin Russell Morga Rf filter/resonator with protruding tabs
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
WO2019040878A1 (en) * 2017-08-25 2019-02-28 L. Perrigo Company PHARMACEUTICAL SUSPENSIONS FOR BISMUTH SUBSALICYLATES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
ES2362418T3 (es) 1997-12-08 2011-07-05 Nycomed Gmbh Nueva forma de supositorio que comprende un compuesto activo ácido-lábil.
HU228181B1 (en) 1999-02-23 2013-01-28 Merck Sharp & Dohme Pharmaceutical composition containing proton pump inhibitors
CA2376202C (en) 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
SI1341524T1 (sl) 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
AU2002221939A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Rapidly disintegrating tablet comprising an acid-labile active ingredient

Also Published As

Publication number Publication date
JP5009482B2 (ja) 2012-08-22
WO2002045692A1 (en) 2002-06-13
AU2002234545A1 (en) 2002-06-18
KR20030059318A (ko) 2003-07-07
CN100528232C (zh) 2009-08-19
US7357943B2 (en) 2008-04-15
CN1541091A (zh) 2004-10-27
US20040052832A1 (en) 2004-03-18
CA2430824C (en) 2012-05-08
EP1341523B1 (en) 2013-01-23
ES2403238T3 (es) 2013-05-16
JP2004514735A (ja) 2004-05-20
EP1341523A1 (en) 2003-09-10
CA2430824A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
BR0115989A (pt) Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
CY1112510T1 (el) Φαρμακευτικο παρασκευασμα υπο τη μορφη παστας το οποιο περιεχει ενα ασταθες στα οξεα δραστικο συστατικο
BR0115987A (pt) Preparação farmacêutica compreendendo um ativo disperso em uma matriz
TW200630123A (en) Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
AR017984A1 (es) Proceso para formar una composicion farmaceutica de topiramato y composicion farmaceutica de topiramato
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
KR20220044558A (ko) 칸나비디올을 포함하는 외용 제제, 조성물의 제조 방법 및 이의 용도
HUP0402154A2 (hu) Metformint és glibenklamidot tartalmazó gyógyászati készítmény II-es típusú diabetes mellitus kezelésére
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
HUP0303454A2 (hu) 4-Ciano-trifluor-3-(4-fluor-fenil-szulfonil)-2-hidroxi-2-metil-propiono-m-toluididet és pvp-t tartalmazó szilárd gyógyászati készítmény
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
US10888541B2 (en) Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
ES2099649T3 (es) Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida.
AU2008253776A8 (en) Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
PT1150660E (pt) Formulacao farmaceutica efervescente contendo metamizole

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: ALTERADO DE: ALTANA PHARMA AG

B25A Requested transfer of rights approved

Owner name: DR. RANGO DIETRICH (DE)

Free format text: TRANSFERIDO DE: NYCOMED GMBH

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.